Skip to main content
Premium Trial:

Request an Annual Quote

NanoString nCounter Vantage Assays

Nanostring Technologies has launched its nCounter Vantage assay portfolio to power 3D biology experiments in cancer research. The portfolio includes two new RNA panels for the detection of fusion genes in lung cancer and leukemia samples, two new protein panels covering solid tumor biology and immune-cell signaling, and one new DNA panel for the detection of single nucleotide variations. The assays allow for multiplexed, digital analysis of DNA, RNA and protein simultaneously in a single experiment, the company said.

The new assays will be featured at the American Association for Cancer Research's annual meeting taking place in New Orleans, April 17-20.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.